H. Ohgaki

Genetics · 2004–2018

A researcher in the Science corpus: 11 papers; trusts 4 researchers and is trusted by 9 researchers here, as inferred from the citation graph.

Subfields

Whom H. Ohgaki trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. P. Kleihues
  2. A. E. Pegg
  3. D. Louis
  4. Takuya Watanabe
  5. Scott W. Lowe
  6. S. Nobusawa
  7. Patrick S. Ward

Who trusts H. Ohgaki overall

  1. P. Kleihues
  2. McKinsey L. Goodenberger
  3. S. Nobusawa
  4. Takuya Watanabe
  5. P. Delgado-López
  6. D. Louis
  7. R. Jenkins
  8. Frank M. Sacks
  9. Ethan G. Cerami
  10. E. Corrales-García

Papers from H. Ohgaki's perspective

Ordered by how strongly the researchers H. Ohgaki trusts endorse each paper. Same corpus, a different order for every researcher.

  1. An Integrated Genomic Analysis of Human Glioblastoma Multiforme (Science)
  2. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (Nature)
  3. Analysis of the IDH1 codon 132 mutation in brain tumors (Acta Neuropathologica)
  4. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. (Cancer Cell)
  5. IDH1 and IDH2 mutations in gliomas. (New England Journal of Medicine)
  6. Pathology and genetics of tumours of the nervous system.
  7. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. (Cancer Cell)
  8. Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α (Science)
  9. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. (The Lancet)
  10. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation (Cancer Cell)

Their papers